Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer
نویسندگان
چکیده
منابع مشابه
Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol
AbstractBreast cancer is a multifactorial disease. Benign breast disease (BBD) is one of the most important risk factors for breast cancer. The etiology of BBD is unknown. It is divided into nonproliferative and proliferative diseases. The selection of studies will be based on titles, abstract screening, inclusion and exclusion criteria, and quality assessment. Previous studies have shown that ...
متن کاملCan Prostate Specific Antigen Be Used as New Biomarker for Early Diagnosis of Breast Cancer?
Introduction: As a glycoprotein, Plasma Prostate-Specific Antigen (PSA) is mainly produced by prostate epithelial cells and is used as a major diagnostic tool for prostate cancer. A group of researchers relate the elevated number of estrogen receptors in breast cancer samples to the over-production of PSA in this type of cancer. Therefore, the present study aimed to determine the participants' ...
متن کاملSubtypes of Benign Breast Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses
Background: Researchers suggest that benign breast disease (BBD) is a key risk factor for breast cancer. The present study aimed to determinate the risk level of breast cancer in terms of various BBD subgroups.Methods: A meta-analysis was performed to determinate the risk of breast cancer associated with BBD. Observational studies (traditional case-control studies, nested case-control studies, ...
متن کاملCXCL12/CXCR4 Gene Polymorphism as a Putative Prognostic Factor for Metastasizing Breast Cancer under Chemotherapy
The receptor and the receptor axis CXCL12 / CXCR4 are the two pairs studied in the metastasis of breast cancer. The purpose of this study was to investigate the relationship between the occurrence of CXCR4 / CXCL12 genes polymorphism and the clinical and pathological characteristics of patients with metastatic breast cancer under chemotherapy. Material and methods: Genomic DNA was extracted f...
متن کاملHGF-MET as a breast cancer biomarker
in preclinical studies, few clinical trials of MET inhibitors have demonstrated the expected therapeutic benefits. This inconsistency raises the possibilities that there are different subsets of MET/HGF-aberrant breast cancer with different responses to MET/HGF-targeted therapies and that MET inhibitors benefit only a particular subgroup of patients. To fully realize the benefits of MET inhibit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: IEEE Transactions on Biomedical Engineering
سال: 2018
ISSN: 0018-9294,1558-2531
DOI: 10.1109/tbme.2017.2695103